Edoxaban tosylate hydrate is a hydrate that is the monohydrate of the tosylate salt of edoxaban. Used for the treatment of deep vein thrombosis and pulmonary embolism. It has a role as an anticoagulant, a platelet aggregation inhibitor and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It contains an edoxaban tosylate.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Edoxaban Tosylate Monohydrate
Drug Overview
What is Edoxaban Tosylate Monohydrate?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Edoxaban Tosylate Monohydrate is the tosylate salt of edoxaban in its monohydrate form, a factor Xa inhibitor. This form may be handled as the active pharmaceutical ingredient, so a toxicological assessment helps define exposure limits and manage cross-contamination risk in shared equipment.
A PDE or ADE sets a health-based limit on daily exposure to Edoxaban Tosylate Monohydrate from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
Where a substance has been used therapeutically, clinical data and the lowest therapeutic dose can provide useful information on human exposure and effects. These data may support or refine the health-based limit, but they must be weighed against non-clinical findings and the quality of the evidence. The report should document how therapeutic information was used and any limitations.
A toxicological assessment characterizes the potential health hazards of Edoxaban Tosylate Monohydrate using the available data. It supports scientifically justified exposure limits, helps manufacturers choose proportionate handling and containment measures, and gives a documented basis for protecting workers and preventing cross-contamination in shared facilities.
Relevant evidence may include repeat-dose toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, and pharmacological activity where available. The critical effect is selected based on data quality and relevance. When data are limited, a documented, risk-based approach is used to address the gaps.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Edoxaban Tosylate Monohydrate in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
A PDE or ADE is a health-based limit on daily exposure through a defined route, usually applied to carryover of Edoxaban Tosylate Monohydrate into the next product. An OEL is a limit on airborne exposure for workers over a stated period. The two answer different questions, so each should be derived and documented separately, with its own rationale and assumptions.
A Masuu Global report for Edoxaban Tosylate Monohydrate presents the scientific rationale, the calculations, and clear recommendations for the assessed limit. It is prepared by certified toxicologists and designed to be regulatory-ready. The report follows a scientifically justified, risk-based approach, so reviewers can trace how each conclusion was reached and which assumptions were applied.
In shared facilities, the PDE is used to calculate acceptance limits for residues of Edoxaban Tosylate Monohydrate that may remain on equipment surfaces after cleaning. These limits are combined with batch size, equipment surface area, and the maximum daily dose of the next product. A documented, health-based limit helps show that cleaning procedures control carryover to a justified level.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Edoxaban Tosylate Monohydrate to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
